Specialty Pharmaceuticals Canada

  • ACT: An Emerging Leader in Specialty PharmaceuticalsACT: An Emerging Leader in Specialty Pharmaceuticals

    ACT: An Emerging Leader in Specialty Pharmaceuticals

  • A Generics Leader in 60+ Global MarketsA Generics Leader in 60+ Global Markets

    A Generics Leader in 60+ Global Markets

  • A Specialty Brands Leader in Women’s HealthA Specialty Brands Leader in Women’s Health

    A Specialty Brands Leader in Women’s Health

  • Expanding Specialty Brands into Key Global MarketsExpanding Specialty Brands into Key Global Markets

    Expanding Specialty Brands into Key Global Markets

  • Accelerating a Foundation in BiosimilarsAccelerating a Foundation in Biosimilars

    Accelerating a Foundation in Biosimilars

Actavis Specialty Pharmaceuticals Co., is the Canadian subsidiary of Actavis plc (NYSE: ACT). We are engaged in the marketing, sale and distribution of branded pharmaceutical products within the Canadian market.

In October 2013, Actavis (NYSE: ACT) announced the acquisition of Warner Chilcott plc, creating an $11 billion leading specialty pharmaceutical company with over $3 billion in pro forma sales.

News

News Archive

Products

We are focused on delivering innovative products that address key therapeutic categories in Urology and in Women's Health.

Fibristal TM Actavis Canada

In Canada, Actavis specialty products include Fibristal™, Androderm®, Rapaflo®, Gelnique® and Oxytrol®

More about Actavis products


Global R&D

Actavis has a growing Specialty Brands pipeline, driven by Women’s Health and Urology products.

Actavis continues to focus its business development efforts on finding new opportunities to invest in this business and to add additional products to the pipeline.


Our pipeline currently has a number of products in various stages of development in Women’s Health and Urology.

Learn about R&D at Actavis